XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03355612
Phase
PHASE3
Status
Unknown

Conditions

  • Gastric Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib: 500 mg, qd, po, last 180 days
  • XELOX — DRUG
    Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w

Study Details

This is a randomized, multicenter, controlled study to compared the Efficacy and Safety of XELOX combined with Apatinib versus XELOX as post-operative chemotherapy in locally advanced gastric signet ring carcinoma with D2 dissection.

Key Dates

Start date
Dec 20, 2017
Status verified
Nov 2017
Primary completion
Dec 20, 2020
Completion
Dec 20, 2025

Study Design

Enrollment
456 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
  • Active Comparator: active comparator
    Drug:XELOX(Capecitabine and Oxaliplatin)

Primary Outcome Measure

Disease Free Survival(DFS) [ Time Frame: 5 years ]

Central Contacts

Related Studies